Ophthalmic Business News

The FDA accepted a new drug application for NOV03, an investigational treatment for the signs and symptoms of dry eye disease, according to a press release from Bausch + Lomb and Novaliq.

If you are a physician who follows the financial media, amid the stories of gloom and doom, you have likely heard of a new investment strategy being offered by many financial institutions called direct indexing.

In the final part of a 12-part series, Peter J. Polack, MD, FACS, explains his fifth website conversion tactic.

Dagny Zhu, MD, and Susan MacDonald, MD, talk with Michelle T. Cabrera, MD, Himani Goyal, MD, and Nicole Fram, MD, about managing and overcoming complications in the OR, ways to instill confidence in young female surgeons and more.

Glaukos and iVeena Delivery Systems have entered into a strategic licensing agreement that grants Glaukos an exclusive global license to develop and commercialize IVMED-80 for the treatment of keratoconus, according to a press release.

Topline 24-month data showed a clinically meaningful reduction in geographic atrophy lesion growth from baseline for intravitreal pegcetacoplan compared with sham in the phase 3 DERBY and OAKS studies, according to Apellis Pharmaceuticals.

Sight Sciences has launched Sion, a bladeless device used to perform goniotomy.

In this episode, Jose O. Segura, wealth management advisor and certified business exit planner, discusses establishing objectives within financial planning and organization, how to diversify your portfolio in ever-changing markets and more.

Alcon has entered into a definitive merger agreement to acquire Aerie Pharmaceuticals in a deal worth approximately $770 million, according to a press release.

A phase 3 pivotal study of PL9643, a melanocortin agonist under investigation as a treatment for dry eye disease, demonstrated positive interim results, according to a press release from Palatin Technologies.